An Accessible Valuation Framework for ASX Stocks CSL and Hub24 in Focus for 2026

The Quick Take

• CSL Ltd (ASX:CSL) and Hub24 Ltd (ASX:HUB) are among the key Australian shares under valuation focus in 2026.
• Rask Media outlines a straightforward methodology for assessing intrinsic value of these two ASX-listed stocks.
• CSL's plasma-derived therapies business and HUB's wealth platform growth underpin their respective investment cases.
• The article targets retail investors seeking an accessible approach to valuing quality ASX growth companies.

CSL Ltd and Hub24 Ltd are drawing valuation attention from Australian retail investors in 2026, with financial media outlet Rask Media providing a simplified methodology for assessing the intrinsic value of both stocks. CSL, one of the ASX's largest companies by market capitalization, operates a global plasma-derived therapies and vaccine business, while Hub24 runs an investment and superannuation platform that has gained significant market share from incumbents over the past several years. Both companies represent the premium-quality growth end of the ASX universe.

For CSL, the primary valuation driver is the recovery trajectory of plasma collection volumes post-pandemic and the growth pipeline of recombinant therapies. A DCF or earnings-yield framework typically anchors CSL valuation to its long-run earnings growth rate of high single digits, adjusted for near-term margin headwinds. Hub24's valuation is more sensitive to funds-under-administration growth and fee compression dynamics in Australia's superannuation and managed accounts sector. Peer wealth platforms including Netwealth and Praemium are direct competitors that provide market share context.

Watch CSL's next earnings update for plasma collection cost normalization progress and pipeline updates on garadacimab and other novel therapies. For HUB, track quarterly funds-under-administration growth disclosures as the primary leading metric for revenue growth. The macro variable for both: Australian equity market sentiment and the RBA's interest rate trajectory determine the discount rate assumptions that underpin fair-value estimates for these long-duration growth stocks.

Synthesized from 1 source.